Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Depreciation and Depletion: 2017-2025

Historic Depreciation and Depletion for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $100,000.

  • Aclaris Therapeutics' Depreciation and Depletion fell 50.00% to $100,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $400,000, marking a year-over-year decrease of 50.00%. This contributed to the annual value of $700,000 for FY2024, which is 12.50% down from last year.
  • As of Q3 2025, Aclaris Therapeutics' Depreciation and Depletion stood at $100,000, which was down 0.00% from $100,000 recorded in Q2 2025.
  • Aclaris Therapeutics' 5-year Depreciation and Depletion high stood at $200,000 for Q1 2021, and its period low was $100,000 during Q4 2022.
  • Over the past 3 years, Aclaris Therapeutics' median Depreciation and Depletion value was $200,000 (recorded in 2024), while the average stood at $163,636.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first slumped by 50.00% in 2022, then surged by 100.00% in 2023.
  • Quarterly analysis of 5 years shows Aclaris Therapeutics' Depreciation and Depletion stood at $200,000 in 2021, then plummeted by 50.00% to $100,000 in 2022, then spiked by 100.00% to $200,000 in 2023, then plummeted by 50.00% to $100,000 in 2024, then plummeted by 50.00% to $100,000 in 2025.
  • Its Depreciation and Depletion was $100,000 in Q3 2025, compared to $100,000 in Q2 2025 and $100,000 in Q1 2025.